Maxim analyst Jason McCarthy downgraded Vistagen (VTGN) to Hold from Buy after the company announced that the PALISADE-3 Phase 3 study of intranasal fasedienol for the acute treatment of social anxiety disorder did not demonstrate a statistically significant improvement on its primary endpoint.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VTGN:
- Vistagen downgraded to Market Perform from Outperform at William Blair
- Vistagen downgraded to Market Perform at William Blair after PALISADE-3 miss
- Vistagen downgraded to Hold at Stifel after PALISADE-3 study disappoints
- Vistagen downgraded to Hold from Buy at Stifel
- Vistagen downgraded to Neutral from Buy at Lucid Capital